Multiscale de novo drug design is a new paradigm that combines mtk-QSBER models, chemical reasoning and a computational variant of FBDD named fragment-based topological design.
No takes yet. Share an insight, caveat, or question.
Alejandro Speck‐Planche (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: